CAMBRIDGE, Mass., April 13 /CNW/ -- Mersana, a cancer therapeutics
company, announced today that results of preclinical studies with its lead
product candidate, XMT-1001, will be presented in two posters at the 2007
Annual Meeting of the American Association of Cancer Research (AACR) taking
place April 14-18th in Los Angeles, CA. Full text of the abstracts can be
viewed online at the AACR website at http://www.AACR.org.
The presentation schedule is as follows:
Abstract #781 "XMT-1001, a novel polymeric prodrug of camptothecin, is a
potent inhibitor of LS174 and A2780 human tumor xenografts in a mouse model"
will be presented in a poster session on Sunday, April 15th from 8:00 am -
12:00 pm. Alex Yurkovetskiy and Russell C. Petter are the presenting authors.
Abstract #4723 "Pharmacokinetics of a novel camptothecin conjugate (XMT-
1001) in the rat and dog" will be presented in a poster session on Tuesday,
April 17th from 1:00 - 5:00 pm. Ullrich Schwertschlag and Alex Yurkovetskiy
are the presenting authors.
XMT-1001 is Mersana's most advanced Fleximer(R)-based product candidate.
It utilizes a novel, dual release mechanism to liberate a camptothecin
prodrug, which is then converted within cells into camptothecin, a DNA
topoisomerase I inhibitor. In preclinical studies, XMT-1001 was better
tolerated and more efficacious than either camptothecin or irinotecan in
models of human cancer, showing extended plasma half-life and high
concentrations in tumor tissue.
About Fleximer Technology
Fleximer(R) technology improves the therapeutic index of cytotoxic
compounds useful as anti-cancer agents by uniquely combining biodegradability
with "biological stealth" properties, making Fleximer(R) materials and their
conjugates long-circulating and non-immunotoxic. Fleximer(R) molecules are
characterized by solubility in water, stability in common manufacturing
procedures and in normal physiological conditions, and non-enzymatic
biodegradability upon uptake by cells.
About Mersana Therapeutics, Inc.
Mersana, a privately held, venture-backed company, is developing novel
oncology agents based on clinically validated drugs through the use of
Fleximer(R), a proprietary bio-degradable and bio-inert material that enhances
the pharmacokinetics, safety, and solubility of drugs. Mersana has an
exclusive license from the Massachusetts General Hospital for its core
technologies. Mersana's pipeline includes compounds with activity against
multiple tumor types and human proof-of-concept that are improved by its
proprietary technologies. Mersana's investors include Fidelity Biosciences,
ProQuest Investments, Rho Ventures, Harris & Harris Group and PureTech
For further information:
For further information: Pete Leone, COO of Mersana, +1-617-498-0020 Web